Ongoing Studies
Adolescent Schizophrenia
University Hospitals Cleveland Medical Center is currently conducting a research study and enrolling adolescent patients to enroll in Naben, an eight-week study of the efficacy and safety of the medication Naben (Sodium Benzoate), as an add-on treatment of schizophrenia in adolescents. Naben is enrolling clinically stable (with residual symptoms), male and female participants in good physical health ages 12-17, with a primary diagnosis of schizophrenia. Participants may not turn 17 before the end of the study. Participants must have an unchanged anti-psychotic regimen for at least eight weeks prior to entry in the study. Other eligibility criteria may apply. For additional questions regarding the study or eligibility requirements, please contact Becky Weintraub at 216-844-3922, or dwcc@uhhospitals.org.
Autism Study
University Hospitals Cleveland Medical Center is currently enrolling children and adolescents between the ages of 5-17 year diagnosed with autism spectrum disorder. This is a 24 week study that is looking at the efficacy and safety of an investigational medication to possibly improve social behavior and communication. Eligible participants may receive a thorough psychiatric evaluation, investigational study drug and close follow up from a pediatric psychiatrist. To learn more, please call 216-844-3922, or dwcc@uhhospitals.org.
Bipolar
University Hospital Cleveland Medical Center is currently conducting a research study and enrolling subjects for Pfizer, a seven-week study to investigate the safety and effectiveness of Geodon as a treatment for pediatric mania in association with bipolar disorder in pediatric patients 10-17 years. Current symptoms supporting the diagnosis must be present for at least seven days prior to screening. Other eligibility criteria may apply. For additional questions regarding the study or eligibility requirements, please call 216-844-3922, or dwcc@uhhospitals.org.
Child and Adolescent Depression Study
University Hospitals Cleveland Medical Center is currently enrolling children and adolescents between the ages of 7-17 diagnosed with major depressive disorder for a clinical research study. Eligible participants may receive a thorough psychiatric evaluation, investigational study drug and close follow up from a pediatric psychiatrist. To learn more call 216-844-3922, or dwcc@uhhospitals.org.
qEEG In Adolescent Depression (ENGINE) Study
The purpose of this study is to examine connections in the brain as they relate to depression in adolescence measured by qEEG technology.
Upcoming Studies
- Adult Schizophrenia Studies
- Pediatric ADHD